Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer
Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer
复制标题
DOI：
10.3109/1354750x.2015.1068853
复制
发表时间：
2015-05
期刊：
影响因子：
2.6
通讯作者：
B. Pan;Dehai Che;Jingyan Cao;Jing Shen;Shi Jin;Yongxu Zhou;Fang Liu;Kuo Gu;Yingchun Man;Li-hua Shang;Yan Yu
中科院分区：
文献类型：
--
作者：
B. Pan;Dehai Che;Jingyan Cao;Jing Shen;Shi Jin;Yongxu Zhou;Fang Liu;Kuo Gu;Yingchun Man;Li-hua Shang;Yan Yu
摘要 目的：探讨血清白细胞介素17（IL-17）在非小细胞肺癌（NSCLC）患者中的临床作用。材料和方法：通过免疫组织化学方法测量 58 例 NSCLC 组织中 IL-17 的表达和微血管密度 (MVD)。通过酶联免疫吸附测定分析 NSCLC 患者 (n = 43) 和健康对照 (n = 37) 的血清 IL-17 和 VEGF 水平。结果：NSCLC患者血清IL-17升高，且其水平与VEGF浓度呈正相关。多变量分析显示血清IL-17水平是NSCLC的独立预后因素。结论：IL-17可能通过促进血管生成在NSCLC进展中发挥作用。
Abstract Objective: The aim of this study was to explore the clinical role of serum interleukin-17 in patients with non-small-cell lung cancer (NSCLC). Materials and method: IL-17 expression and microvessel density (MVD) were measured via immunohistochemistry in 58 NSCLC tissues. Serum IL-17 and VEGF levels in NSCLC patients (n = 43) and healthy controls (n = 37) were analyzed via enzyme-linked immunosorbent assay. Results: Serum IL-17 was elevated and the levels positively correlated with VEGF concentration in NSCLC patients. Multivariate analyses revealed that serum IL-17 levels were an independent prognostic factor in NSCLC. Conclusion: IL-17 may play a role in NSCLC progression by promoting angiogenesis.